

Docket: 7213.13

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:

Charles N. Serhan

Application No.:

10/663,061

Filing Date:

September 12, 2003

Examiner:

Title:

Aspirin-Triggered Lipid Mediators

Group Art Unit:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(B)

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 I hereby certify that this document is being sent via First Class U.S. mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this **7** day of **O** c. , 2003.

Dear Sir:

Pursuant to 37 CFR § 1.97(b), the references listed on the attached Form PTO-1449 (1 sheet, submitted in duplicate) are brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the identified references are enclosed as necessary. This IDS is being filed before the mailing of a first office action on the merits. In accordance with 37 CFR § 1.97(b), no statement or fee is required.

Additionally, a Protest Under 37 CFR § 1.291(a) and a Third Party Submission of Patents or Publications Under 37 CFR § 1.99 were filed in the parent application (U.S. Ser. No. 09/785,866). Copies of these documents and the references are being supplied herewith.

It should be noted that U.S. Patent No. 5,409,955, issued to Bockow et al., was cited in the parent application and is also cited in the Information Disclosure Statement under 37 CFR § 1.97(b) attached herewith.

Respectfully submitted,

DORSEY & WHITNEY LLP Customer Number 25763

Date: Jewel 17, 2003

Scott D. Rothenberger Reg. No. 41,277

Intellectual Property Department

**Suite 1500** 

50 South Sixth Street

Minneapolis, MN 55402-1498

(612) 340-8819

PTO/SB/08A	(10/01)	(modified)
	- 05 00	

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC

Substitu	te for fo	rm 1449A/F	PTO	PER	\$ 5 m	Application Numb r	10/663,061				
INE		MATIO	NI F	NSCT A	DEMARI	Filing Date	S ptember 12, 2003				
INFORMATION DISCEOSURE STATEMENT BY APPLICANT				First Named Inv ntor	Charles N. Serhan						
317						Art Unit					
(use as many sheets as necessary)				Examiner Name							
She t	1	of 1				Attorney Docket Number	ber 7213.13				
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS											
*Examiner	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue						TRANSLATION YES NO			
		number(s), publisher, city and/or country where published  Eritsland et al., "Effects of Highly Concentrated Omega-3 PUF As and Acetylsalicylic							NO		
		Acid, Alone and Combined, on Bleeding Time and Serum Liquid Profile", <i>J, Olso City Hosp.</i> , Vol. 39 (8-9), pp. 97-101, 1989.									
		lacoviello et al., "Modulation of Fibrinolytic Response to Venous Occlusion in Humans by a Combination of Low-Dose Aspirin and n-3 PUFAs", <i>Arteriosclerosis Thrombosis</i> , Vol. 10, pp. 1191-1197, 1992.									
		Lau et al., "Effects of Fish Oil Supplementation on Non-Steroidal Anti-Inflammatory Drug (NSAID) Requirement in Patients with Mild Rheumatoid Arthritis – A Double-Blind Placebo Controlled Study", <i>British Journal of Rheumatology</i> , Vol. 32 (11), pp. 982-989. 1993.									
						gy of Cyclooxygenase Inhib led., Vol. 18 (1), pp. 119-131,					
EXAMI	NER SI	GNATURE				DATE CONSIDERED					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											